# **Review Form 1.6**

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_69684
Title of the Manuscript:	Synthetic Advances against Coronaviruses: A Short Review of the Recent Literature on Various Synthetic Methods and Recently Developed Strategies
Type of the Article	Mini-Review Article

## **General guideline for Peer Review process:**

This journal's peer review policy states that <u>NO</u> manuscript should be rejected only on the basis of '<u>lack of Novelty'</u>, provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://peerreviewcentral.com/page/manuscript-withdrawal-policy)

## **PART 1:** Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments		
Minor REVISION comments	I have gone through entire mini review, based on my assumption that authors were collected material & done good work. There are some correction has to do.  1. In page No 5, not able to understand what it means? Lost 3 lines have to modify.  2. I suggest authors that already antiviral drugs are not effective against SARS CoV – virus, new molecule up to which level will be effective can't predict.  3. I request authors to modify & rewrite full references.  By doing these corrections, it may be consider.	
Optional/General comments		

## PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

### **Reviewer Details:**

Name:	Senthilraja. M
Department, University & Country	J. K. K. Nattraja College of Pharmacy, India

Created by: EA Checked by: ME Approved by: CEO Version: 1.6 (10-04-2018)